DiaMedica Therapeutics Inc. (DMAC) income statement
DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$8.59+0.21 (+2.51%)
Close on Nov 18, 2026Market cap $463.22MP/E –Yield –
DiaMedica Therapeutics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -67.7%
Financial strength
- Current ratio
- 6.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 77.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 12.08
- Dividend yield
- –
See a number that looks wrong?